NEW YORK, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Royal Caribbean Group (NYSE: RCL), Mesoblast Limited (NASDAQ: MESO), Loop Industries, Inc. (NASDAQ: LOOP), and Turquoise Hill Resources Ltd. (NYSE: TRQ). Stockholders have until the deadlines below to petition the court to serve as lead plaintiff. Additional information about each case can be found at the link
Royal Caribbean Group (NYSE: RCL)
Class Period: February 4, 2020 to March 17, 2020
Lead Plaintiff Deadline: December 7, 2020
The complaint, filed on October 7, 2020, alleges that throughout the Class Period defendants failed to disclose material facts about the Companys decrease in bookings outside China, instead maintaining that it was only experiencing a slowdown in bookings from China. The Action further alleges that defendants failed to disclose material facts about the Companys inadequate policies and procedures to prevent the spread of COVID-19 on its ships. The truth about the scope of the impact that COVID-19 had on the Companys overall bookings and the inability of Royal Caribbean to prevent the virus spread on its ships was revealed through a series of disclosures.
First, on February 13, 2020, Royal Caribbean issued a press release stating that it had canceled 18 voyages in Southeast Asia due to recent travel restrictions and further warning that recent bookings had been softer for its broader business.
On this news, Royal Caribbean shares fell over 3 percent.
Second, on February 25, 2020, Royal Caribbean filed its 2019 Form 10-K, indicating that COVID-19 concerns were negatively impacting its overall business.
On this news, Royal Caribbean shares fell over 14 percent.
Third, on March 10, 2020, Royal Caribbean withdrew its 2020 financial guidance, increased its revolving credit facility by $550 million, and announced that it would take cost-cutting actions due to the proliferation of COVID-19, further revealing that COVID-19 was severely impacting Royal Caribbeans 2020 customer booking and that its safety measures were inadequate to prevent the spread of the virus on its ships.
On this news, Royal Caribbean shares fell over 14 percent.
Fourth, on March 11, 2020, Royal Caribbeans largest competitor, Carnival, announced a 60-day suspension of all operations, prompting concern that Royal Caribbean would follow suit. At the same time, Royal Caribbean also cancelled two cruises, beginning a series of cancellations and suspensions to follow.
On this news, Royal Caribbean shares fell almost 32 percent.
Fifth, on March 14, 2020, Royal Caribbean announced a suspension of all global cruises for 30 days.
On this news, Royal Caribbean stock fell over 7 percent.
Sixth, on March 16, 2020, the Company revealed that global operations could be suspended longer than anticipated, announcing the cancellations of two additional cruises throughout April and into May.
On this news, Royal Caribbean shares fell over 7 percent.
Finally, on March 18, 2020, analysts downgraded Royal Caribbeans stock and slashed their price targets.
On this news, Royal Caribbean shares fell more than 19 percent.
For more information on the Royal Caribbean class action go to: https://bespc.com/cases/RCL
Mesoblast Limited (NASDAQ: MESO)
Class Period: April 16, 2019 to October 1, 2020
Lead Plaintiff Deadline: December 7, 2020
Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial to treat children with steroid refractory acute graft versus host disease (aGVHD).
In early 2020, Mesoblast completed its rolling submission of its Biologics License Application (BLA) with the FDA to secure marketing authorization to commercialize remestemcel-L for children with steroid refractory aGVHD.
On August 11, 2020, the FDA released briefing materials for its Oncologic Drugs Advisory Committee (ODAC) meeting to be held on August 13, 2020. Therein, the FDA stated that Mesoblast provided post hoc analyses of other studies to further establish the appropriateness of 45% as the null Day-28 ORR for its primary endpoint. The briefing materials stated that, due to design differences between these historical studies and Mesoblasts submitted study, it is unclear that these study results are relevant to the proposed indication.
On this news, the Companys share price fell $6.09, or approximately 35%, to close at $11.33 per share on August 11, 2020.
On October 1, 2020, Mesoblast disclosed that it had received a Complete Response Letter (CRL) from the FDA regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that the Company conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD. The CRL also identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the products biologic activity.
On this news, the Companys share price fell $6.56, or 35%, to close at $12.03 per share on October 2, 2020.
The complaint, filed on October 8, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that comparative analyses between Mesoblasts Phase 3 trial and three historical studies did not support the effectiveness of remestemcel-L for steroid refractory aGVHD due to design differences between the four studies; (2) that, as a result, the FDA was reasonably likely to require further clinical studies; (3) that, as a result, the commercialization of remestemcel-L in the U.S. was likely to be delayed; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
For more information on the Mesoblast class action go to: https://bespc.com/cases/MESO
Loop Industries, Inc. (NASDAQ: LOOP)
Class Period: September 24, 2018 to October 12, 2020
Lead Plaintiff Deadline: December 14, 2020
On October 13, 2020, Hindenburg Research published a report alleging, among other things, that Loops scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the companys process internally. The report also stated that Loops previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were technically and industrially impossible, according to a former employee. Moreover, the report alleged that Executives from a division of key partner Thyssenkrupp, who Loop entered into a global alliance agreement with in December 2018, told us their partnership is on indefinite hold and that Loop underestimated both costs and complexities of its process.
On this news, the Companys share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.
The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Companys business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loops purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loops announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants positive statements about the Companys business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
For more information on the Loop class action go to: https://bespc.com/cases/Loop
Turquoise Hill Resources Ltd. (NYSE: TRQ)
Class Period: July 17, 2018 to July 31, 2019
Lead Plaintiff Deadline: December 14, 2020
Turquoise Hill is an international mining company focused on the operation and development of the Oyu Tolgoi copper-gold mine in Southern Mongolia (Oyu Tolgoi), which is the Companys principal and only material resource property. Turquoise Hills subsidiary, Oyu Tolgoi LLC, holds a 66% interest in Oyu Tolgoi, and the remainder is held by the Government of Mongolia.
Rio Tinto plc and Rio Tinto Limited are operated and managed together as single economic unit and engage in mining and metals operations in approximately 35 countries. Through their subsidiaries, Rio Tinto owns 50.8% of Turquoise Hill. A Rio Tinto subsidiary, Rio Tinto International Holdings, Inc. (Rio Tinto International or RTIH; and collectively with Rio Tinto plc and Rio Tinto Limited, Rio Tinto), is also the manager of the Oyu Tolgoi project, including having responsibility for its development and construction.
On July 31, 2019, Turquoise Hill issued a press release and Management Discussion & Analysis (MD&A) making further disclosures about the status of the project, including that Turquoise Hill took a $600 million impairment charge and a substantial deferred income tax recognition adjustment tied to the Oyu Tolgoi project, and that it suffered a loss in the second quarter. The next day, before the market open, Rio Tinto issued a release concerning in part the project status, including that it had also taken an impairment charge related to the Oyu Tolgoi project, of $800 million.
Following this news, on August 1, 2019, Turquoise Hills common stock price closed at $0.53 per share, down 8.62% from the prior days closing price of $0.58 per share.
The complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements and omitted to disclose material facts regarding the Companys business and operations. Specifically, defendants made false and or misleading statements and/or failed to disclose that: (i) the progress of underground development of Oyu Tolgoi was not proceeding as planned; (ii) there were significant undisclosed underground stability issues that called into question the design of the mine, the projected cost and timing of production; (iii) the Companys publicly disclosed estimates of the cost, date of completion and dates for production from the underground mine were not achievable; (iv) the development capital required for the underground development of Oyu Tolgoi would cost substantially more than a billion dollars over what the Company had represented; and (v) Turquoise Hill would require additional financing and/or equity to complete the project.
For more information on the Turquoise Hill class action go to: https://bespc.com/cases/TRQ
About Bragar Eagel & Squire, P.C.:Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit http://www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact Information:Bragar Eagel & Squire, P.C.Brandon Walker, Esq. Melissa Fortunato, Esq.Marion Passmore, Esq.(212) 355-4648investigations@bespc.comwww.bespc.com
Go here to see the original:
Bragar Eagel & Squire, PC Reminds Investors That Class Action Lawsuits Have Been Filed Against Royal Caribbean, Mesoblast, Loop Industries, and...
- Global Induced Pluripotent Stem Cell ((iPSC) Market to Reach $0 Thousand by 2027 - Yahoo Finance - October 13th, 2022
- Paris-based startup Gourmey uses the Big Idea Ventures accelerator program as a launch pad and goes on to raise the world's largest cultivated meat... - October 13th, 2022
- The New York Stem Cell Foundation Mourns the Loss of CEO Susan L. Solomon - October 4th, 2022
- In Multiple Myeloma, Will ASCT Survive Collision With CAR T-Cell Therapy? - Targeted Oncology - October 4th, 2022
- The global live cell imaging market is expected to grow at a CAGR of 8.44% during 2022-2027 - Benzinga - October 4th, 2022
- Sernova to Participate in the Roth Inaugural Healthcare Opportunities Conference - Sernova (OTC:SEOVF) - Benzinga - October 4th, 2022
- New Study Finds Mouse Embryonic Stem Cells Have No Special - September 25th, 2022
- GMAs Robin Roberts replaced by Cecilia Vega as host is still absent from morning show following emotional... - The US Sun - September 25th, 2022
- Severe COVID-19 caused by senile interferon response in older patients, researchers suggest - EurekAlert - September 25th, 2022
- Money on the Move: Arsenal, ILiAD and a Hefty Gift to UCSD - BioSpace - September 8th, 2022
- How surviving cancer changed this 34-year-olds attitude toward work: The concept of checking email was laughable - CNBC - September 8th, 2022
- Garuda Therapeutics Announces Appointment of Roger Sawhney, M.D., as Chief Financial Officer - Benzinga - September 8th, 2022
- 6 Ingredients to Avoid Putting on Your Skin - Healthline - September 8th, 2022
- Scientists create 'synthetic' embryo with brain, beating heart in 'world first' - New York Post - August 30th, 2022
- Global Cell Banking Outsourcing Market to Grow at a CAGR of ~18% during 2022-2031; Market to Expand Owing to the Development of Advanced Cell... - August 30th, 2022
- Pelvic Reconstruction Market is projected to reach a valuation of US$ 366.9 million by 2032, at a CAGR of 2.8% during 2022-2032 Future Market... - August 30th, 2022
- Global Mesenchymal Stem Cell (MSC) Market to Grow at a CAGR of ~14% during 2022-2031; Market to Grow on the Back of Increasing Prevalence of Chronic... - August 5th, 2022
- Pigs died after heart attacks. Scientists brought their cells back to life. - Popular Science - August 5th, 2022
- Global Hematopoietic Stem Cell Transplant (HSCT) Market to be Driven by Increasing Prevalence of Blood Ca - Benzinga - August 5th, 2022
- Why Are There so Many Books and Shows About Cannibalism? - The New York Times - July 27th, 2022
- Cell Culture Media Market: Competitive Approach, Breakdown And Forecast by 2027 - Digital Journal - July 27th, 2022
- Herminia Pasantes revealed one of taurines big roles in the brain - Science News Magazine - July 27th, 2022
- Shai Efrati, MD, the World's Leading Research Scientist and Innovator in Hyperbaric Medicine, to Keynote at the Global Wellness Summit - PR Web - July 27th, 2022
- Journalist Benita Alexander reveals chilling clue that told her Miracle Man Paolo Macchiarini was a rom... - The US Sun - July 27th, 2022
- Melanoma Kills Nearly Twice The Number Of Men Than Women: Study - Kaiser Health News - July 19th, 2022
- Patients have turned to pricey 'blood washing' to treat long COVID - New York Post - July 19th, 2022
- Affimed Presents Preclinical Data of Novel Innate Cell Engager AFM28 at the Annual Meeting of the European Hematology Association (EHA) -... - July 11th, 2022
- Interferons Market is anticipated to reach US$ 13.8 Bn by 2032, at a CAGR of 3.9% from 2022 to 2032 - Digital Journal - July 11th, 2022
- 'World's Greatest Tuba-Playing Car Salesman' Bounces Back after Leukemia, Thanks to Wilmot Team - URMC - July 3rd, 2022
- Hadjiargyrou Is New York Tech's First Distinguished Professor | Box | New York Tech - New York Institute of Technology - July 3rd, 2022
- The global tissue engineering market is anticipated to reach US$ 13,236.87 million in 2022 and is project - Benzinga - July 3rd, 2022
- He Helped Cure the London Patient of H.I.V. Then He Turned to Covid. - The New York Times - June 13th, 2022
- Biden to Pause New Solar Tariffs as White House Aims to Boost Adoption - The New York Times - June 13th, 2022
- Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference - Business Wire - June 4th, 2022
- ReCode Therapeutics to Present at Jefferies Healthcare Conference - Benzinga - Benzinga - June 4th, 2022
- A Medical History of Transplant Surgery Thats Not for the Squeamish - The New York Times - May 15th, 2022
- Mesenchymal Stem Cells Market to Witness Growth Acceleration | Celprogen Inc., Thermo Fisher Scientific, Inc. Queen Anne and Mangolia News - Queen... - May 15th, 2022
- CORRECTING and REPLACING Paracrine Announces Appointment of Biotech Veteran David H. Crean, Ph.D. to the Board of Directors - Business Wire - May 15th, 2022
- William Blair Begins Coverage on Century Therapeutics (NASDAQ:IPSC) - Defense World - May 15th, 2022
- Aging Brain Initiative awards fund five new ideas to study, fight neurodegeneration - MIT News - May 2nd, 2022
- Treadwell Therapeutics Announces Fast Track Designation Granted by the FDA to CFI-400945 for the Treatment of Acute Myeloid Leukemia - PR Newswire - May 2nd, 2022
- What's Trending in the World of Hair Treatments - NewBeauty Magazine - May 2nd, 2022
- Demand in the US Animal Model Market is set to Increase at a 4.1% CAGR from 2022 to 2032 - Future Market Insights - PR Newswire - May 2nd, 2022
- Actinium Pharmaceuticals, Inc. and Immedica Announce Commercialization Agreement for Iomab-B (131I apamistamab) in Europe, the Middle East and North... - April 19th, 2022
- BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure - GlobeNewswire - March 25th, 2022
- Hoth Therapeutics Announces it Has Successfully Completed Manufacturing Feasibility of the HT-KIT Drug Substance - Yahoo Finance - March 25th, 2022
- Emendo Biotherapeutics and Seattle Children's Research Institute Announce Collaboration to Develop CRISPR-based Therapeutic Strategy for Severe... - December 24th, 2021
- 2021: The year in review | YaleNews - Yale News - December 24th, 2021
- 15 Truly Unbelievable Ways Science Changed the World in 2021 - Fatherly - December 24th, 2021
- Cargo Dragon Docks to Station with Brand New Science - NASA - December 24th, 2021
- Adaptation Is Key to Advancing Care for Adult Patients With Leukemia - OncLive - December 24th, 2021
- Cytovia Therapeutics' Scientific Leadership to Present at Upcoming Conferences - Business Wire - December 10th, 2021
- A New Stem-Cell Treatment Looks to Have Cured a Man of Type 1 Diabetes - Good News Network - December 10th, 2021
- BrainStorm Cell Therapeutics and Catalent Announce Completion of Technology Transfer for NurOwn Manufacturing - PRNewswire - December 10th, 2021
- Affimed to Host Virtual Investor Call Today to Discuss Treatment of CD30-positive Lymphoma ... - The Bakersfield Californian - December 10th, 2021
- No animals harmed in new chip drug tests that are faster and cheaper - ISRAEL21c - December 10th, 2021
- Stem Cell Therapy for Heart Failure Reduced Major Cardiac Events and Death - Diagnostic and Interventional Cardiology - November 22nd, 2021
- Global Cord Blood Stem Cells Market With An Annual Growth Rate, The Impact Of Covid-19: FAQ The UK Directory - The UK Directory - November 22nd, 2021
- The Beauty Products Violet Greys Cassandra Grey Uses to the Last Drop - The Cut - November 22nd, 2021
- Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual... - October 16th, 2021
- Holy wars against vaccines and science People's World - People's World - October 16th, 2021
- Judge Rules to Uphold Religious Exemption to NY Vax Mandate - wnbf.com - October 16th, 2021
- Investigators Aim to Fill Unmet Need of Intermediate- to High-Risk MDS With ENHANCE Trial - OncLive - October 16th, 2021
- Healthcare Researchers Are Putting HUMAN Immune Systems In Pigs To Study Illnesses-Here's The Tech Behind It - Tech Times - October 5th, 2021
- Losing Your Hair? You Might Blame the Great Stem Cell Escape. - The New York Times - October 5th, 2021
- BrainStorm to Present at the 2021 Cell & Gene Meeting on the Mesa - KKTV 11 News - October 5th, 2021
- Coronavirus: What's happening in Canada and around the world on Tuesday - CBC.ca - October 5th, 2021
- Why Bezos, Musk, Page and other billionaires want to live forever - New York Post - October 5th, 2021
- Court hears dispute over N.Y. healthcare workers seeking COVID vaccine religious exemption - Washington Times - October 5th, 2021
- Glioma subtype may hold the secret to the success of immunotherapies - Michigan Medicine - October 5th, 2021
- Vera Nall: Misinformation will kill us in Southwest Missouri - Joplin Globe - October 5th, 2021
- Meet the Newest Group of Tenured, Tenure-Track Faculty at UT Dallas - University of Texas at Dallas - October 5th, 2021
- Global Stem Cell Banking Market to Reach US$11.3 Billion by the Year 2027 - Yahoo Finance - August 5th, 2021
- COVID-19 Antibody Therapy Now Available For Treatment and Post-Exposure Prophylaxis - PrecisionVaccinations - August 5th, 2021
- Primary Cells Market Research Report by Origin, by Cell Type, by End-user, by Region - Global Forecast to 2026 - Cumulative Impact of COVID-19 - Yahoo... - August 5th, 2021
- BeyondSpring Announces Positive Topline Results from its DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for the Treatment... - August 5th, 2021
- 5 days, 11 life science IPOs & more than $1.3B in new capital - MedCity News - August 5th, 2021
- What Its Like To Have Severe Iron Deficiency Anemia - Scary Mommy - August 5th, 2021
- 'Black fungus' infections on the rise in India: report - New York Post - June 23rd, 2021
- Global Cord Stem Cell Banking Market Status, Business Trends, Competitive Analysis, Growth Factors and Forecasts To 2028||Cryo-Cell International,... - June 23rd, 2021